Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' quadrivalent influenza vaccine · 1 trial · 1 indication
Antibody titers were expressed as Geometric mean titers (GMTs).The vaccine influenza strains included A/Solomon Islands,A/Wisconsin,B/Malaysia and B/Jiangsu antigens.
| Arm | Type | Description |
|---|---|---|
| Quadrivalent influenza vaccine GSK 2115160A Group 1 | EXPERIMENTAL | Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0 |
| Quadrivalent influenza vaccine GSK 2115160A Group 2 | EXPERIMENTAL | Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0 |
| Trivalent influenza vaccine GSK 2115160A Group 1 | ACTIVE_COMPARATOR | Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0 |
| Trivalent influenza vaccine GSK 2115160A Group 2 | ACTIVE_COMPARATOR | Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0 |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' quadrivalent influenza vaccine | BIOLOGICAL | Single intramuscular dose on Day 0. |
| GSK Biologicals' trivalent influenza vaccine | BIOLOGICAL | Single intramuscular dose on Day 0. |
Inclusion Criteria: * Healthy subjects as established by medical history and clinical examination before entering into the study. * Subjects who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and inclu...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
GSK Biologicals' quadrivalent influenza vaccine is an investigational vaccine developed by GSK plc for the prevention of influenza. It is designed to protect against influenza virus infection and is in Phase 1 clinical development. The vaccine has been studied in one completed Phase 1 trial.
GSK Biologicals' quadrivalent influenza vaccine is being developed for the prevention of influenza. It is intended for use in adults, with the completed Phase 1 trial enrolling healthy volunteers aged 18 years and older. The vaccine remains investigational and is not approved for use.
GSK Biologicals' quadrivalent influenza vaccine is developed by GSK plc, which trades under the ticker GSK. GSK Biologicals is the vaccine division of GSK plc. The company is responsible for the clinical development of this influenza vaccine candidate.
GSK Biologicals' quadrivalent influenza vaccine is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The vaccine is investigational and has not been approved by the FDA or any regulatory authority.
GSK Biologicals' quadrivalent influenza vaccine has been studied in one completed Phase 1 trial, NCT00714285, titled "Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults." The trial enrolled 420 adults in Czechia, was randomized and active-controlled, and included healthy volunteers aged 18 years and older.